Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
RNAC
RNAC
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RNAC News
Cartesian Therapeutics Reports Disappointing FY Earnings with Significant Revenue Decline
1d ago
seekingalpha
Cartesian Therapeutics Grants Stock Options to New Employees
Feb 03 2026
Newsfilter
Cartesian Advances Descartes-08 Clinical Trials for Autoimmune Diseases
Jan 09 2026
Globenewswire
Cartesian Advances Descartes-08 Clinical Trials for Autoimmune Diseases
Jan 09 2026
Newsfilter
Johnson & Johnson Reports Positive Phase 2b Results for Lupus Drug Nipocalimab, Plans Phase 3 Trial
Jan 06 2026
Benzinga
Cartesian Therapeutics Grants 7,350 Stock Options to New Employees at $6.76 Exercise Price
Jan 06 2026
Globenewswire
Cartesian Therapeutics Appoints Adrian Bot to Board, Enhancing Cell Therapy Expertise
Dec 18 2025
Globenewswire
Cartesian Therapeutics Appoints Adrian Bot, M.D., Ph.D. to Board of Directors
Dec 18 2025
Newsfilter
After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences
Dec 09 2025
NASDAQ.COM
HC Wainwright & Co. Reaffirms Buy Rating for Cartesian Therapeutics, Adjusts Price Target to $30
Nov 19 2025
Benzinga
Cartesian Halts Lupus and Multiple Myeloma Research to Redirect Development Efforts
Nov 14 2025
Benzinga
Nvidia Set for Potential 18% Surge? Check Out 10 Leading Analyst Predictions for Friday
Nov 14 2025
Benzinga
Cartesian Therapeutics Unveils New Employment Incentive Grants
Oct 30 2025
Newsfilter
Repligen (RGEN) Exceeds Expectations in Q3 Earnings and Revenue
Oct 28 2025
NASDAQ.COM
Positive Momentum for Cartesian Therapeutics, Inc. (RNAC): Will Its 8.2% Increase Lead to Further Gains?
Oct 21 2025
NASDAQ.COM
Biotech Stocks Surge in After-Hours Trading on Friday in Anticipation of Important Clinical Trial Announcements
Sep 22 2025
NASDAQ.COM
Show More News
